vs

Side-by-side financial comparison of Princeton Bancorp, Inc. (BPRN) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $20.7M, roughly 1.8× Princeton Bancorp, Inc.). On growth, Princeton Bancorp, Inc. posted the faster year-over-year revenue change (3.6% vs -57.1%). Over the past eight quarters, Princeton Bancorp, Inc.'s revenue compounded faster (9.1% CAGR vs -46.5%).

Princeton Bancorp, Inc. is a U.S.-based bank holding company operating through its community banking subsidiary. It offers retail and commercial banking products including deposit accounts, small business loans, consumer loans, mortgages and wealth management services, primarily serving clients across New Jersey and the U.S. mid-Atlantic region.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

BPRN vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.8× larger
ORGO
$37.2M
$20.7M
BPRN
Growing faster (revenue YoY)
BPRN
BPRN
+60.6% gap
BPRN
3.6%
-57.1%
ORGO
Faster 2-yr revenue CAGR
BPRN
BPRN
Annualised
BPRN
9.1%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BPRN
BPRN
ORGO
ORGO
Revenue
$20.7M
$37.2M
Net Profit
$6.1M
Gross Margin
30.8%
Operating Margin
38.2%
-185.1%
Net Margin
29.3%
Revenue YoY
3.6%
-57.1%
Net Profit YoY
16.3%
EPS (diluted)
$0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BPRN
BPRN
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$20.7M
$225.6M
Q3 25
$21.5M
$150.9M
Q2 25
$21.1M
$101.0M
Q1 25
$20.9M
$86.7M
Q4 24
$20.0M
$126.7M
Q3 24
$19.2M
$115.2M
Q2 24
$18.1M
$130.2M
Net Profit
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
$6.1M
$43.7M
Q3 25
$6.5M
$21.6M
Q2 25
$688.0K
$-9.4M
Q1 25
$5.4M
$-18.8M
Q4 24
$5.2M
$7.7M
Q3 24
$-4.5M
$12.3M
Q2 24
$5.1M
$-17.0M
Gross Margin
BPRN
BPRN
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
BPRN
BPRN
ORGO
ORGO
Q1 26
-185.1%
Q4 25
38.2%
28.1%
Q3 25
38.5%
13.7%
Q2 25
2.8%
-12.5%
Q1 25
32.9%
-30.9%
Q4 24
34.0%
8.1%
Q3 24
-29.1%
5.4%
Q2 24
34.1%
-10.7%
Net Margin
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
29.3%
19.4%
Q3 25
30.0%
14.3%
Q2 25
3.3%
-9.3%
Q1 25
25.7%
-21.7%
Q4 24
26.1%
6.1%
Q3 24
-23.3%
10.7%
Q2 24
28.4%
-13.1%
EPS (diluted)
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
$0.89
$0.31
Q3 25
$0.95
$0.11
Q2 25
$0.10
$-0.10
Q1 25
$0.77
$-0.17
Q4 24
$0.75
$0.05
Q3 24
$-0.68
$0.09
Q2 24
$0.80
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BPRN
BPRN
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$270.7M
Total Assets
$2.3B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BPRN
BPRN
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
Q3 25
$0
Q2 25
$10.0M
Q1 25
Q4 24
$0
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
$270.7M
$300.1M
Q3 25
$266.6M
$255.1M
Q2 25
$261.9M
$233.2M
Q1 25
$267.0M
$242.9M
Q4 24
$262.0M
$262.9M
Q3 24
$261.5M
$278.5M
Q2 24
$244.8M
$263.5M
Total Assets
BPRN
BPRN
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$2.3B
$598.7M
Q3 25
$2.2B
$509.8M
Q2 25
$2.2B
$461.1M
Q1 25
$2.3B
$467.4M
Q4 24
$2.3B
$497.9M
Q3 24
$2.4B
$446.3M
Q2 24
$2.0B
$443.2M
Debt / Equity
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
Q3 25
0.00×
Q2 25
0.04×
Q1 25
Q4 24
0.00×
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BPRN
BPRN
ORGO
ORGO
Operating Cash FlowLast quarter
$21.5M
Free Cash FlowOCF − Capex
$20.6M
FCF MarginFCF / Revenue
99.3%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$29.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
$21.5M
$39.4M
Q3 25
$4.9M
$3.1M
Q2 25
$3.1M
$-32.9M
Q1 25
$1.3M
$-19.9M
Q4 24
$14.7M
$10.9M
Q3 24
$1.2M
$8.7M
Q2 24
$4.3M
$4.7M
Free Cash Flow
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
$20.6M
$34.8M
Q3 25
$4.7M
$844.0K
Q2 25
$2.9M
$-36.5M
Q1 25
$1.1M
$-23.6M
Q4 24
$13.2M
$7.6M
Q3 24
$766.0K
$6.1M
Q2 24
$3.9M
$2.9M
FCF Margin
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
99.3%
15.4%
Q3 25
21.6%
0.6%
Q2 25
13.7%
-36.1%
Q1 25
5.0%
-27.2%
Q4 24
65.9%
6.0%
Q3 24
4.0%
5.3%
Q2 24
21.8%
2.2%
Capex Intensity
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
4.3%
2.1%
Q3 25
1.1%
1.5%
Q2 25
1.2%
3.6%
Q1 25
1.0%
4.2%
Q4 24
7.6%
2.7%
Q3 24
2.2%
2.2%
Q2 24
2.1%
1.4%
Cash Conversion
BPRN
BPRN
ORGO
ORGO
Q1 26
Q4 25
3.54×
0.90×
Q3 25
0.76×
0.14×
Q2 25
4.57×
Q1 25
0.23×
Q4 24
2.82×
1.43×
Q3 24
0.71×
Q2 24
0.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons